| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1706431/0001193125-26-151209.txt","as_of":"2026-04-11T03:10:51.104915+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1706431/0001193125-26-151209.txt","company":"Vir Biotechnology, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1706431/0001193125-26-151209.txt","article_chars":1823,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_1c021890cf6fa484","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1706431/0001193125-26-151209.txt","content_type":"text/plain","enriched_at":"2026-04-11T05:10:11.033992+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"8-K","final_url":"https://www.sec.gov/Archives/edgar/data/1706431/0001193125-26-151209.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1706431/0001193125-26-151209.txt","source_event_id":"evt_86b93c4e4b61","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"77105b356efb9d91","kind":"sec_filing","published_at":"20260410","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-07","2026-04-24","2026-04-11"],"entities":[{"asset_class":"equity","name":"Vir Biotechnology, Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"person","name":"Mark Eisner, MD, MPH","relevance":"high","symbol":"","type":"person"},{"asset_class":"equity","name":"Vir Biotechnology, Inc. (the Company)","relevance":"medium","symbol":"","type":"issuer"}],"event_type":"other","information_gaps":["No prior known state is provided in the signal, so the exact change vs prior disclosure cannot be determined.","The filing\u2019s SEC \u201cDate of Report (Date of earliest event reported)\u201d field is not populated in the cleaned text, so the earliest-event date is not explicitly confirmed from the article text.","No details are provided about whether Eisner\u2019s departure is voluntary or involuntary, whether there are transition arrangements, or any compensatory arrangements.","No successor name or timing for appointment is disclosed in the provided text."],"key_facts":["Form type: 8-K (Current Report).","Item 5.02 is disclosed: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","On April 7, 2026, Mark Eisner, MD, MPH (Executive Vice President and Chief Medical Officer), informed the Company he will step down.","Eisner\u2019s stepping down is effective April 24, 2026.","The Company initiated a search for Eisner\u2019s successor."],"numeric_claims":[{"label":"Effective date of stepping down","value":"2026-04-24"},{"label":"Date Eisner informed the Company","value":"2026-04-07"}],"primary_claim":"Mark Eisner will step down as Vir\u2019s Executive Vice President and Chief Medical Officer effective April 24, 2026, per the company\u2019s April 7, 2026 notice.","relevance_score":0.45,"sentiment":"neutral","source_quality":"medium","summary":"Vir Biotechnology, Inc. filed a Form 8-K reporting that Mark Eisner, MD, MPH, will step down as Executive Vice President and Chief Medical Officer effective April 24, 2026, and the company has initiated a search for a successor.","topics":["SEC filing","Form 8-K","executive officer departure","director/officer transition","succession search"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Vir Biotechnology, Inc. \u00b7 Filed 20260410","ticker":"VIR","tickers":["VIR"],"title":"VIR filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1706431/0001193125-26-151209.txt"}... |